Independent associations between cardiovascular risk factors and glucometabolic markers with long-term mortality by multivariate Cox regression analysis

Observational data extracted from DIGAMI 1 study

Patient Groups
All (240 of 620)Control (138 of 314)Intensive insulin (102 of 306)
ParameterRR (95% CI)PRR (95% CI)PRR (95% CI)P
Age (1 added year)1.08 (1.06-1.11)< 0.0011.09 (1.06-1.12)< 0.0011.08 (1.05-1.12)< 0.001
Male sex1.12(0.82-1.54)0.460.97 (0.63-1.49)0.881.44 (0.88-2.32)0.15
Previous disease

Myocardial infarction
1.22 (0.87-1.70)0.251.10 (0.69-1.77)0.681.40 (0.86-2.28)0.16
Congestive heart failure2.24 (1.60-3.14)< 0.0012.37 (1.50-3.74)< 0.0012.28 (1.33-3.73)< 0.01
Hypertension1.01 (0.75-1.35)0.961.15 (0.78-1.71)0.480.86 (0.55-1.36)0.52
Smoker1.08 (0.69-1.68)0.741.05 (0.57-1.93)0.871.25 (0.62-2.52)0.53
Diabetes duration (1 added year)1.02 (1.01-1.03)< 0.011.01 (0.99-1.03)0.211.03 (1.01-1.05)< 0.01
Admission

Blood glucose +1mmol/l
1.06 (1.03-1.10)< 0.011.06 (1.01-1.11)< 0.051.05 (0.99-1.11)0.065
HbA1c +1%1.09 (1.00-1.18)0.0541.15 (1.03-1.29)< 0.051.03 (0.90-1.17)0.66

From: Appendix E, Evidence tables

Cover of Hyperglycaemia in Acute Coronary Syndromes
Hyperglycaemia in Acute Coronary Syndromes: Management of Hyperglycaemia in People with Acute Coronary Syndromes.
NICE Clinical Guidelines, No. 130.
Centre for Clinical Practice at NICE (UK).
Copyright © 2011, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.